TB-500 is widely discussed alongside BPC-157 as a "repair" compound. This
monograph clarifies what TB-500 actually is and how it relates to thymosin
beta-4 (which has its own monograph in this library).
Chemical identity & structure.
TB-500 is a synthetic peptide marketed as corresponding to the biologically
active region of the natural protein thymosin beta-4 (TB4). TB4 itself is a
43-amino-acid protein; TB-500 in the research-product market is a shorter
synthetic peptide associated with TB4's actin-binding domain (the region around
the well-studied "LKKTETQ" motif). The practical point: **TB-500 and thymosin
beta-4 are related but not identical** — TB-500 is a fragment-based synthetic
product, not the full endogenous protein.
Mechanism of action.
The mechanisms attributed to TB-500 derive from TB4 biology. TB4's best-
characterized role is regulating actin — the cytoskeletal protein involved in
cell movement. Through actin regulation, TB4 (and by extension TB-500) is
reported to promote cell migration, support angiogenesis, and modulate
inflammation — all relevant to tissue repair. These mechanisms should be read as
extrapolated from TB4 research.
Key research findings.
The preclinical literature reports effects in models of muscle, tendon, and
cardiac repair, and wound healing. As with BPC-157, the breadth of reported repair effects warrants
caution.
The research / citation base.
There are no published human clinical trials of TB-500 specifically. Thymosin
beta-4 (the full protein) has been studied in some human clinical research
contexts — but TB-500 the research product is not the same molecule, and the
human evidence for TB-500 itself is absent. Treat efficacy claims accordingly.
Human clinical trial data.
No human clinical trial has established administration parameters for TB-500; VialTalk does not provide community-sourced dosing.
Quality & sourcing notes.
Because "TB-500" products vary in exactly what fragment they contain, the COA
matters more than usual: it should state the precise sequence and report
identity by mass spectrometry plus HPLC purity. A vendor that cannot tell you
the exact peptide in the vial has not earned trust.
*Research-use note: Educational summary of published research. TB-500 is not an
approved drug; this is research context only and not medical advice.*
